#USA #Miami #Baird Medical #microwave ablation #NASOIE

Baird Medical Accelerates U.S. Expansion at NASOIE 2026

Baird Medical Investment Holdings Ltd., trading under NASDAQ as BDMD, is poised to accelerate its U.S. expansion efforts with its participation in the highly anticipated 2026 Annual Meeting of the North American Society of Interventional Endocrinologists (NASOIE), set to take place in Miami, Florida. Known for its advancements in minimally invasive Microwave Ablation (MWA) technology, Baird Medical's commitment to enhancing physician education and patient access is clearly demonstrated through this initiative.

Engaging with Top Clinicians

The NASOIE conference serves as a gathering point for leading clinicians specializing in interventional endocrinology. At this year's event, Baird Medical aims to engage deeply with attending physicians. Company representatives will present discussions on the clinical applications and effectiveness of their proprietary MWA technology. These interactions are instrumental as medical professionals seek to integrate advanced tools into their practice, ultimately striving for enhanced patient outcomes.

Through the exchange of insights, Baird Medical looks to provide evidence-based information regarding its cutting-edge technologies that reduce patient recovery times while ensuring effectiveness in treating various conditions. This year's conference is undeniably an opportunity for Baird Medical to showcase its innovations while gathering invaluable feedback for its future endeavors.

Clinical Feedback to Shape Future Direction

The insights gathered from the clinical feedback during this conference will play a crucial role in shaping Baird Medical's commercial strategies going forward. The company is committed to delivering medical devices that address a wide range of clinical applications, ensuring precision in their implementation.

About Baird Medical

Baird Medical specializes in minimally invasive diagnostics and treatment, focusing on the research and development of surgical robotic systems and innovative surgical instruments. The company's mission centers around enhancing patient outcomes through precision technology and advanced diagnostic solutions. Baird Medical aims to foster collaborations with top-tier academic institutions, striving to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies.

With FDA 510(k) certification, Baird Medical's solutions have been utilized in over 30 prestigious hospitals and clinics across the United States, including renowned institutions such as the Mayo Clinic and UCSF Medical Center. The company is also recognized as a market leader in China for thyroid microwave ablation devices, gradually expanding its commercial presence across more than 20 countries worldwide.

Looking Ahead

As Baird Medical continues its journey towards greater accessibility in healthcare through innovative minimally invasive therapies, it recognizes the pivotal role of conferences like NASOIE in facilitating collaboration and knowledge sharing among healthcare professionals. This continued engagement underscores Baird Medical's commitment to improving patient care through advanced technology and education.

The future looks promising for Baird Medical as it seeks to leverage its recent engagements at NASOIE to drive growth in the U.S. market while solidifying its position as a leader in the medical device space. The company's ongoing dedication to research and development is expected to lead to further advancements in treatment methodologies, with the potential to redefine how minimally invasive procedures are conducted in various medical fields.